Compare Fidelity National Information Servcs Inc (FIS) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs Neurocrine Biosciences Inc — how do they compare? Fidelity National Information Servcs Inc trades at $34.49 (market cap $17.71B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B). The key difference: Fidelity National Information Servcs Inc is the larger of the two by market cap, and Fidelity National Information Servcs Inc pays a 5.13% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fidelity National Information Servcs Inc for 88 Days and Neurocrine Biosciences Inc for 23 Days on average.
| FIS | NBIX | |
|---|---|---|
Market Cap | $17.71B | $14.60B |
Volume | 9,047,825 | 1,075,694 |
Sector | Technology | Health |
52-Week High | $68.57 | $185.50 |
52-Week Low | $32.44 | $123.10 |
Typical Hold Time | 88 Days | 23 Days |
Enterprise Value | $38.22B | $14.61B |
Dividend Yield | 5.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS trades at $33.82, up 1.2% today, with a bearish technical signal and neutral oscillators. The stock shows attractive valuation with a P/E of 5.2 and P/S of 1.44, supported by a 27.65% net income margin and 22.33% ROE. Recent earnings beat expectations in Q1 and Q2 2026, and the company secured multiple core banking client wins, enhancing growth prospects.
Outlook is positive given low valuations and earnings momentum, but risks include high debt levels and inconsistent cash flow. Analyst consensus is bullish with a $47.54 price target, implying significant upside. Investors should monitor execution on revenue growth and debt management.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
